Mechanistically, resistance to CDK4/6i in HER2+BC may arise through an intrinsic versus acquired mutation, or due to activation of alternative signaling pathways such as Aurora kinase A, AKT, and MAPK [182,183]. This evidence concerns the gene ERBB2 and breast cancer.